The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thu ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would become an oncology powerhouse with $8 billion blockbuster medications. Celgene share price surges 21% as Bristol-Myers Squibb (BMS) announces this acquisition. When the deal closes, Celgene shareholders would receive one BMS share, $50 in cash for each Celgene share, and one tradeable contingent value right for each share of Celgene. This contingent value right entitles its holder to gain a one-time potential payment of $9 in cash upon FDA approval of all 3 main medications of ozanimod (31 December 2020), liso-cel (31 December 2020) and bb2121 (31 March 2021).

BMS already owns a rich portfolio of blockbuster medications. These medications include the top-selling PD-1 checkpoint inhibitor Opdivo, the leukemia drug Sprycel, the melanoma drug Yervoy, the multiple-myeloma drugs Revlimid and Pomalyst, and the pancreatic cancer medicine Abraxane. These medications generate about $5.9 billion revenue in 2018Q3. These landmark medications position BMS as the market-share leader in immune-oncology and hematology.

The BMS specialty market niche and patent portfolio collectively create competitive moats for the new biopharma goliath in comparison to Johnson & Johnson, Merck, Pfizer, Roche, and Novartis etc.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More
U.S. yield curve inversion can be a sign but not a root cause of the next economic recession.
Dan Rochefort

2019-09-19 15:30:00 Thursday ET

U.S. yield curve inversion can be a sign but not a root cause of the next economic recession.

U.S. yield curve inversion can be a sign but not a root cause of the next economic recession. Treasury yield curve inversion helps predict each of the U.S.

+See More
Internal capital markets and financial constraints
Charlene Vos

2022-10-15 09:34:00 Saturday ET

Internal capital markets and financial constraints

Internal capital markets and financial constraints Duchin (JF 2010) empirically finds that multidivisional firms with robust internal capital markets ret

+See More
Elon Musk envisions a bold fantastic future with his professional trifecta of lean enterprises SolarCity, SpaceX, and Tesla.
Joseph Corr

2020-04-10 11:33:00 Friday ET

Elon Musk envisions a bold fantastic future with his professional trifecta of lean enterprises SolarCity, SpaceX, and Tesla.

Elon Musk envisions a bold fantastic future with his professional trifecta of lean startup enterprises SolarCity, SpaceX, and Tesla. Ashlee Vance (2015)

+See More
Mario Draghi declares the ECB agreement on a thorny set of revisions to Basel 3.
Rose Prince

2017-11-25 06:34:00 Saturday ET

Mario Draghi declares the ECB agreement on a thorny set of revisions to Basel 3.

Mario Draghi, President of the European Central Bank, heads the international committee of financial supervisors and has declared their landmark agreement o

+See More
Dr Kai-Fu Lee praises China as the next epicenter of artificial intelligence and smart data analysis.
Peter Prince

2017-12-01 06:30:00 Friday ET

Dr Kai-Fu Lee praises China as the next epicenter of artificial intelligence and smart data analysis.

Dr Kai-Fu Lee praises China as the next epicenter of artificial intelligence, smart data analysis, and robotic automation. With prior IT careers at Apple, M

+See More
CNBC news anchor Becky Quick interviews Warren Buffett in light of the recent stock market gyrations and movements.
Becky Berkman

2018-04-05 07:42:00 Thursday ET

CNBC news anchor Becky Quick interviews Warren Buffett in light of the recent stock market gyrations and movements.

CNBC news anchor Becky Quick interviews Berkshire Hathaway's Warren Buffett in light of the recent stock market gyrations and movements. Warren Buffett

+See More